WASHINGTON: An experimental drug developed by Merck Pharmaceuticals has shown promising results in reducing hepatitis D virus levels and improving liver-related markers in patients with chronic hepatitis D, according to the company.
The drug, brelovitug, is an experimental monoclonal antibody being developed to target a protein associated with hepatitis B virus. Because hepatitis D can only occur in people who are also infected with hepatitis B, researchers are studying the drug as a potential treatment for chronic hepatitis D.
According to the company, the late-stage clinical trial met its primary goal after 24 weeks of treatment.
Among patients receiving a 300-milligram dose, 56% achieved both a reduction in hepatitis D virus levels and normalization of liver enzymes. In the group receiving 900 milligrams, 45% achieved both outcomes.
No patients in the delayed-treatment group achieved both measures during the same period, according to the company.
Merck said the drug was generally tolerated across the different dose groups, with its safety profile consistent with previously reported data.
Hepatitis D is a relatively uncommon viral liver infection that occurs only alongside hepatitis B. It can lead to severe liver disease and, in some cases, serious long-term complications.
The company estimates that around 230,000 people in the United States and Europe are living with hepatitis D.
Merck said full findings from the study will be presented at a future medical congress. The company also plans to submit an application to the US Food and Drug Administration (FDA) for approval of brelovitug during the first half of 2027.
The drug remains investigational and has not yet been established as an approved treatment for hepatitis D.